Articles with public access mandates - Yi ZhangLearn more
Not available anywhere: 1
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score
PL Jerevall, J Brock, J Palazzo, T Wieczorek, M Misialek, AJ Guidi, Y Wu, ...
Breast Cancer Research and Treatment 173, 375-383, 2019
Mandates: Swedish Research Council
Available somewhere: 17
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ...
Journal of clinical oncology 26 (20), 3324-3330, 2008
Mandates: US National Institutes of Health
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene …
DC Sgroi, I Sestak, J Cuzick, Y Zhang, CA Schnabel, B Schroeder, ...
The lancet oncology 14 (11), 1067-1076, 2013
Mandates: US National Institutes of Health, Cancer Research UK
Breast cancer index identifies early-stage estrogen receptor–positive breast cancer patients at risk for early-and late-distant recurrence
Y Zhang, CA Schnabel, BE Schroeder, PL Jerevall, RC Jankowitz, ...
Clinical Cancer Research 19 (15), 4196-4205, 2013
Mandates: US National Institutes of Health
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker
DC Sgroi, E Carney, E Zarrella, L Steffel, SN Binns, DM Finkelstein, ...
Journal of the National Cancer Institute 105 (14), 1036-1042, 2013
Mandates: US National Institutes of Health
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More?(aTTom) trial
JMS Bartlett, DC Sgroi, K Treuner, Y Zhang, I Ahmed, T Piper, R Salunga, ...
Annals of Oncology 30 (11), 1776-1783, 2019
Mandates: Cancer Research UK, Ontario Institute for Cancer Research
Molecular profiles of progesterone receptor loss in human breast tumors
CJ Creighton, C Kent Osborne, MJ van de Vijver, JA Foekens, JG Klijn, ...
Breast cancer research and treatment 114, 287-299, 2009
Mandates: US National Institutes of Health
A tissue systems pathology assay for high-risk Barrett's esophagus
RJ Critchley-Thorne, LC Duits, JW Prichard, JM Davison, BA Jobe, ...
Cancer Epidemiology, Biomarkers & Prevention 25 (6), 958-968, 2016
Mandates: US National Institutes of Health
Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett's esophagus
JM Davison, J Goldblum, US Grewal, K McGrath, K Fasanella, C Deitrick, ...
Official journal of the American College of Gastroenterology| ACG 115 (6 …, 2020
Mandates: US National Institutes of Health
A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett's esophagus
RJ Critchley-Thorne, JM Davison, JW Prichard, LM Reese, Y Zhang, ...
Cancer Epidemiology, Biomarkers & Prevention 26 (2), 240-248, 2017
Mandates: US National Institutes of Health
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA. 14 study
DC Sgroi, JAW Chapman, T Badovinac-Crnjevic, E Zarella, S Binns, ...
Breast Cancer Research 18, 1-7, 2016
Mandates: US National Institutes of Health
A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Y Zhang, BE Schroeder, PL Jerevall, A Ly, H Nolan, CA Schnabel, ...
Clinical Cancer Research 23 (23), 7217-7224, 2017
Mandates: US Department of Defense, US National Institutes of Health
Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers
C Yau, Y Wang, Y Zhang, JA Foekens, CC Benz
Breast cancer research and treatment 126, 803-810, 2011
Mandates: US National Institutes of Health
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor–Positive Lymph Node–Negative Early-Stage Breast Cancer
I Sestak, Y Zhang, BE Schroeder, CA Schnabel, M Dowsett, J Cuzick, ...
Clinical Cancer Research 22 (20), 5043-5048, 2016
Mandates: Cancer Research UK, National Institute for Health Research, UK
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
B Schroeder, Y Zhang, O Stål, T Fornander, A Brufsky, DC Sgroi, ...
NPJ Breast Cancer 3 (1), 28, 2017
Mandates: US Department of Defense
Prognostic utility of breast cancer index to stratify distant recurrence risk in invasive lobular carcinoma
R Nunes, T Sella, K Treuner, JM Atkinson, J Wong, Y Zhang, P Exman, ...
Clinical Cancer Research 27 (20), 5688-5696, 2021
Mandates: US National Institutes of Health
Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer
Y Zhang, J Liu, PK Raj-Kumar, LA Sturtz, A Praveen-Kumar, HH Yang, ...
Breast cancer research and treatment 184, 689-698, 2020
Mandates: US Department of Defense, US National Institutes of Health
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2 …
JAW Chapman, DC Sgroi, PE Goss, E Zarella, S Binns, Y Zhang, ...
Breast cancer research and treatment 157, 101-108, 2016
Mandates: Canadian Cancer Society
Publication and funding information is determined automatically by a computer program